Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$-1.11
EPS est.
$-1.07
EPS surprise
-3.35%
1-day move
-0.35%
IDEAYA Biosciences reported a larger-than-expected loss per share, which contributed to a slight decline in its stock price. The company did not provide revenue figures, leaving investors without key insights into its financial health. The stock's modest drop reflects investor concerns over the earnings miss and lack of guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.11 | $-0.98 | -3.35% |
| Revenue | $— | $5M | — |
No transcript is on record, and the analysis is based on numerical results only.
IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for cancer. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as innovation in drug development continues to grow.
Last quarter
In the last quarter, IDEAYA reported an EPS of $-0.94, which was better than analysts' expectations of $-1.03. However, revenue details were not disclosed, leading to a modest stock increase of 1.62% the following day.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
+8284.17%
Avg 1-day reaction
-2.11%
Analysts expect IDEAYA to report a loss of $-0.98 per share on $5 million in revenue. Given the company's history of mixed earnings surprises, investors are cautious.
Bull case
If IDEAYA can beat EPS expectations and show stronger revenue growth, it could signal improved operational efficiency and market acceptance of its therapies.
Bear case
A larger-than-expected loss or disappointing revenue could raise concerns about the company's financial stability and future growth prospects.
Key metrics to watch
EPS
$-0.98Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$5MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will EPS come in better than the consensus estimate of $-0.98?
A beat on EPS could indicate improved financial performance and boost investor confidence.
Q2
What revenue figures will IDEAYA report, and how do they compare to the $5 million consensus?
Revenue performance is crucial for assessing market demand and the company's growth trajectory.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus is overly focused on the expected loss, but IDEAYA's recent operational improvements and potential revenue growth could surprise investors positively.
Supporting evidence
The company has shown a history of beating EPS estimates, which could continue this quarter.
Options pricing suggests a significant move, indicating that the market may be underestimating potential volatility.
Key risk
If IDEAYA reports revenue significantly above $5 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will reflect the company's ability to manage costs and grow revenue amidst a competitive landscape.
Bull confirmed if
Reporting an EPS better than $-0.98 and revenue exceeding $5 million would confirm the bull case.
Bear confirmed if
An EPS worse than $-1.13 or revenue significantly below expectations would confirm the bear case.
What the market is pricing for the move.
Implied Move
±9.08%
Historical Avg
±4.2%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.
Options are pricing ±9.1% while IDYA has averaged ±4.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
52.0%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If IDEAYA beats expectations, history suggests the stock could rise by about 1.24%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the market may react cautiously, leading to minimal movement.
Miss
A miss could result in a decline of around 5.14%, reflecting investor disappointment and concerns over future performance.
The lines on the call that would change the story.